Fundamental Research Funds for Central Universities 2019XZZX001-01-06 (Y.Z.)
For any compound to work transdermally, it must be small enough to penetrate through multiple skin layers and achieve therapeutic concentrations in the bloodstream
Potential complementary evidence of GLP-1RAs and SGLT2is In a meta-analysis comparing the effects of GLP-1RAs with SGLT2is, five GLP-1RA (ELIXA, LEADER, SUSTAIN-6, EXSCEL, and Harmony Outcomes) and three SGLT2i trials (EMPA-REG OUTCOME, CANVAS Program, and DECLARE-TIMI 58) with a total of 77,242 patients were include [35]
More serious side effects are rare but can include allergic reactions
In the STEP UP clinical trial, the 7.2 mg dose produced a mean weight loss of 20.7% at 72 weeks, compared with 17.5% at the previously approved 2.4 mg dose and 2.4% with placebo
(11) Research models of GH deficiencies were examined in the course of this controlled study, where rhIGF-1 was presented once daily to all the models